🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jonathan Siegel

Bayer (United States)

ORCID: 0000-0001-6477-4281

MedicineMathematicsEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).”.

Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2010)10.1200/jco.2010.28.15_suppl.7531

N/A

3.0DataRank · unranked

53 citations

I. N. Bondarenko, A. Luft, P. Serwatowski, Fabrice Barlesi, R. T. Chacko +14 more

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(22)00061-4

N/A

1.5DataRank · unranked

69 citations

Silvia Novello, Alessandra Bearz, Giovanni Luca Ceresoli, Joachim G.J.V. Aerts, James Spicer +22 more

Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma

Scientific Reports(2024)10.1038/s41598-024-62307-5

N/A

0DataRank · unranked

10 citations

Karen Keating, Brian J. Cuffel, Cem Elbi, Jonathan Siegel, Christoph Gerlinger +8 more